Overview

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Study RIN-PF-301 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis (IPF) over a 52-week period.
Phase:
Phase 3
Details
Lead Sponsor:
United Therapeutics
Treatments:
Treprostinil